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Abstract
Purpose of Review Progression rate from islet autoimmunity to clinical diabetes is unpredictable. In this review, we focus on an
intriguing group of slow progressors who have high-risk islet autoantibody profiles but some remain diabetes free for decades.
Recent Findings Birth cohort studies show that islet autoimmunity presents early in life and approximately 70% of indi-
viduals with multiple islet autoantibodies develop clinical symptoms of diabetes within 10 years. Some “at risk” individ-
uals however progress very slowly. Recent genetic studies confirm that approximately half of type 1 diabetes (T1D) is
diagnosed in adulthood. This creates a conundrum; slow progressors cannot account for the number of cases diagnosed in
the adult population.
Summary There is a large “gap” in our understanding of the pathogenesis of adult onset T1D and a need for longitudinal studies
to determine whether there are “at risk” adults in the general population; some of whom are rapid and some slow adult
progressors.
Keywords Type 1 diabetes (T1D) . Slow progression . Adult onset . Islet autoantibodies
Abbreviations
ABIS All babies in Southeast Sweden
BOX Bart’s Oxford family study
DAISY The Diabetes Autoimmunity Study in the Young
GADA Autoantibodies to glutamic acid decarboxylase
GRS Genetic risk scores
GWAS Genome-wide association studies
HLA Human leucocyte antigen
IAA Insulin autoantibodies
IA-2A Autoantibodies to IA-2
LADA Latent autoimmune diabetes in adults
IL2 Interleukin 2
mAabs Multiple autoantibodies
ZnT8A Autoantibodies to zinc transporter 8
Introduction
Type 1 diabetes (T1D) results from a breakdown in immune
regulation that leads to expansion of autoreactive B cells as well
as CD4+ and CD8+ Tcells targeting the insulin-producing beta
cells of the islets of Langerhans [1]. The humoral response
results in circulating autoantibodies to islet antigens including
insulin (IAA) [2], glutamic acid decarboxylase (GADA) [3],
islet antigen-2 (IA-2A) [4], zinc transporter 8 (ZnT8A) [5]
and more recently tetraspanin 7 (Tspan 7A) [6]. It has been
known for some time that progression to clinical diabetes is
not a linear process but proceeds at variable pace in different
individuals [7]. von Herrath et al. [8] suggested a relapsing and
remitting pattern caused by dynamic interactions between im-
mune cells and beta cells. Prospective birth cohort studies show
that autoantibodies can be detected in children at risk of T1D
from 6 months of age with a peak in seroconversion between 2
and 3 years [9] and children who are multiple islet autoantibody
positive early in life have a 70% risk of diabetes within 10 years
and an 84% risk within 15 years [10]. Recent observations of
enriched B cell infiltration in islets from young children
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diagnosed with diabetes under the age of 7 years [11] which
was not observed in those developing the condition over the age
of 13 years, with a heterogenous pattern in between, may sug-
gest that the “later onset” pattern of insulitis would be detected
in pancreas from slow progressors.
Our initial studies in the Bart’s Oxford (BOX) family study of
T1D [12] suggested the presence of multiple islet autoantibody-
positive individuals in whom progression to clinical diabetes was
delayed. We therefore established the Slow or Non-progressive
Autoimmunity to the Islets of Langerhans (SNAIL) cohort to
understand better the natural history of autoimmunity in individ-
uals we describe as “slow progressors” who do not develop
clinical symptoms for more than a decade after detection of mul-
tiple islet autoantibody positivity [13••]. These individuals may
be an example of a slow chronic autoimmunity, and we have
hypothesised that this may be enabled through natural regulation
of the autoimmune process in these individuals.
SNAIL Participants
“At risk” individuals in SNAIL [13••] were derived from five
international studies: BABYDIAB [14], the Diabetes
Autoimmunity Study in the Young (DAISY) [15], All Babies
in Southeast Sweden (ABIS) [16], the BOX Family Study [12]
and the Pittsburgh Family Study [17]. The studies are united by
their focus on the natural history of autoimmune diabetes.
BABYDIAB, DAISY and ABIS included prospective follow-
up of children from birth (blood sampleswere taken at 9months
or 1 year), while BOX and the Pittsburgh studies enrolled first
degree relatives of individuals with diabetes throughout life.
To date, 132 participants have been identified as slow
progressors who remained diabetes free for more than 10 years
after multiple autoantibodies (mAabs) were first detected
(Table 1). These slow progressors represent on average 30%
of the autoantibody-positive individuals identified, but the
frequency varies depending on when islet autoantibodies were
first detected. Given the longitudinal nature of the studies in
SNAIL participants continue to be followed (median 4 years,
IQR 2–9 years). During follow-up, 42 of 132 slow progressors
were diagnosed with T1D indicating that these individuals
remain at high risk although 90 are diabetes free. It is impor-
tant to note that in the birth cohorts, young children from
BABYDIAB and DAISY with multiple autoantibodies were
represented within the SNAIL population showing that slow
progression is not an exclusive characteristic of age of first
multiple islet autoantibody detection. Interestingly, ABIS has
identified multiple antibody-positive individuals through an-
tibody screening in the general population. In this study, how-
ever, only half of the high-risk children identified developed
diabetes within 10 years of follow-up, suggesting that slow
progressors could be more common in the general population
than in those selected through genetic risk or family history.
This may reflect reduced genetic risk and/or environmental
exposures.
Genetic Factors Affecting Rate of Progression
The effect of the HLA class II DRB1*04-DQB1*0302 (DR4-
DQ8) and DRB1*03-DQB1*02 (DR3-DQ2) on increased risk
of T1D is well established [18, 19], but given their role in
antigen presentation, it has been suggested that these class II
haplotypes are involved in the initiation of autoimmunity
while HLA class I haplotypes drive subsequent beta cell de-
struction [20]. Independent genetic determinants of insulitis
and diabetes have been identified in the NOD mouse [21],
and it has been postulated in humans that HLA class I risk
genes (for instance HLAA*24) define rate of progression [20]
perhaps through effects on CD8+ Tcells. In the DAISY study,
however, the HLA class II DR3/4-DQB1*0302 genotype had
a dramatic influence on both development of islet autoimmu-
nity and progression to T1D and the PTPN22(R620W) T allele
significantly influenced progression to persistent islet autoim-
munity [22]. Analysis of progression in the T1D Prediction
and Prevention study (DIPP) cohort suggested protective ef-
fects of the A*03 allele while the B*39 was associated with
seroconversion from one to two islet autoantibodies [23]. In
BABYDIAB, islet autoantibody-positive children with the
rs2111485 GG genotype in the T1D-associated viral-response
gene, interferon-induced helicase C domain-containing pro-
tein 1 (IFIH1), progressed more quickly to diabetes (31%
within 5 years) compared with children carrying the GA or
AA genotypes (11% within 5 years) [24]. This suggests inter-
action between genetic and environmental determinants of
T1D. There is also a suggestion of direct effects of common
genetic variants associatedwith T1D on immune cell function;
for instance, the IL2/IL2-R signalling pathway confers de-
creased ability to respond to IL2 with a resultant relative re-
duction in suppressive Treg function [25]. Genetic variants in
PTPN2 may contribute to this.
Genetic Risk in SNAIL Participants: Slow
Progressors Have Less HLA-Mediated Genetic
Risk than Individuals Diagnosed in Childhood
HLA class II DQB1 risk genotypes were available from 121
slow progressors in SNAIL in the format DQB1*0201/
DQB1*0302 (DQ2/DQ8). The high-risk combination was de-
creased (28% vs 42%) while intermediate risk genotypes were
more common (55% vs 49%) when compared with 348 chil-
dren from BOX diagnosed under 5 years of age, who were
designated rapid progressors (p = 0.011, Table 2).
Nevertheless, the slow progressors are a relatively high-risk
group as their genetic risk profile was similar to that observed
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in 1217 BOX participants diagnosed between 10 and 20 years
of age (DQ2/DQ8, 26%). Only two of 121 (1.7%) slow
progressors carried the protective DQB1*0602 allele, the
same as the proportion found in rapid progressors (1.7%)
[13]. HLA DRB1*04 subtypes are also an important consider-
ation because haplotypes containing DRB1*0403 and *0407
are protective [19]. In the BOX slow progressor cohort, of 22
individuals positive for HLA DRB1*04, subtype data were
available for 19; 13 were positive for *0401, 4 for *0404, 1
for *0405 and 1 for *0408, all susceptible subtypes.
Increasingly, measurements of genetic risk have moved
away from HLA to use of simplified composite genetic risk
scores where HLA and non-HLA risk are combined quantita-
tively using T1D-associated SNPS. The genetic risk scores
(GRS) are weighted by odds ratio and can be useful to help
classify diabetes clinically [26, 27]. Specificity and sensitivity
testing in the Environmental Determinants of Diabetes in the
Young (TEDDY) study show that composite scores (especial-
ly those striving to account for the complexity of the HLA)
improve genetic risk assessment [28]. As GRS are based on
genome-wide association studies (GWAS) which were largely
carried out on children from European populations or popula-
tions of European extraction, broader GWAS are required to
inform risk in other populations [29].
Althoughmost studies of the genetics of T1D have focused
on childhood onset diabetes, recent studies in UK Biobank of
all diagnoses of diabetes using a T1D GRS [30••] showed that
T1D occurs at a consistent rate in each decade of life. Indeed,
as the GRS are based on GWAS data on children diagnosed
with diabetes under the age of 15 years when T1D suscepti-
bility genes are enriched, it is likely that the frequency of adult
onset T1D has been underestimated using this approach.
Nevertheless, this study shows that half of autoimmune T1D
is diagnosed over the age of 30 years. This begs the question
“where do they come from?” or “when was islet autoimmuni-
ty triggered in these patients who are diagnosed as adults?”
Mind the Gap!
As represented schematically in Fig. 1, there is a large gap in
our understanding of the pathogenesis of autoimmune diabe-
tes in adulthood as the majority of previous research has fo-
cused on childhood onset (under the age of 15 years).
Moreover, most birth cohorts do not have extended follow-
up into adulthood.
Birth cohorts show that 84% of children who are positive
for multiple islet autoantibodies early in life develop diabetes
Table 2 The frequency of high-
risk HLA genotypes by age at
onset in the BOX study compared
with slow progressors in the
SNAIL study
Diagnosis age (years) High risk (DQ2/DQ8) Intermediate risk
(either DQ2 or
DQ8)
Low risk (not
DQ2/not DQ8)
BOX probands Under 5 (%) 42.2 49.1 8.6
5–9 (%) 34.9 54.7 10.4
10–14 (%) 30.5 55.4 14.1
15–20 (%) 19.4 62.8 17.8
SPs N/A 28.9 55.4 15.7
Table 1 Description of participants in the SNAIL study
Overall BABY DIAB DAISY ABIS BOX Pittsburgh
n 132 22 30 11 36 33
Age at first antibody test, median (IQR) 7 (1–18) 1 1 (1–2) 1 18 (13–38) 18 (11–33)a
Age at mAab+ sample, median (IQR) 10 (5–20) 5 (2–5) 7 (4–10) 5 18 (13–38) 18 (11–37)
Male, n (%) 69 (54) 16 (73) 17 (57) 7 (64) 15 (42) 17 (52)
Years of follow-up since mAab+ detection, median (IQR) 14 (12–19) 13 (11–14) 12 (11–13) 13 (13–14) 17 (14–24) 20 (13–26)
Diabetes free at follow-up, n (%) 90 (68) 12 (55) 23 (77) 10 (100) 22 (61) 23 (70)
Genetic data available 121 22 30 10 36 23
For birth cohorts BABYDIAB, DAISY and ABIS, the age at first antibody test represents the first early life sample available sample for analysis. For
BOX and the Pittsburgh study, this represents the first available sample after recruitment and there is no information on the time of seroconversion for
these individuals
n number, IQR interquartile range, mAab+ multiple autoantibody positive
(Reproduced from: Long AE, et al. Diabetologia. 2018 61:1484–1490; https://doi.org/10.1007/s00125-018-4591-5; Creative Commons user license
https://creativecommons.org/licenses/by/4.0/) [13]
a Earliest sample available
Curr Diab Rep           (2019) 19:99 Page 3 of 8    99 
within 15 years. Slow progressors as defined in SNAIL can
therefore account for only a small proportion of adult onset
autoimmune diabetes. This leads to some questions we do not
yet know the answer to:
& Do some individuals in the general population seroconvert
to islet autoantibody positivity in late adolescence/
adulthood or do they trigger autoimmunity in early age
but this is more regulated and therefore progress more
slowly, if at all?
& If the rate of onset of diabetes is the same in adulthood and
childhood, are approximately one in three hundred of the
adult UK population “at risk”?
& Do they develop multiple islet autoantibodies?
& Are there adults who progress rapidly from islet autoanti-
body positivity to clinical onset?
& Is the pathogenesis driven by GAD autoimmunity as de-
scribed in cases of latent autoimmune diabetes of adults
(LADA)?
Islet Autoantibody Characteristics in Slow
Progressors
Studies of neonatal diabetes show that most cases of dia-
betes diagnosed before 6 months are unlikely to be
autoimmune, but the majority of those diagnosed after
the age of 6 months have the genetic characteristics of
T1D [31]. Islet autoantibodies are detectable by 5 years
of age in most future childhood T1D cases [32], in many
by 2 years of age [14], and IAA (autoantibodies to insu-
lin, often the first to appear) have been detected as early
as 6 to 12 months of age [33]. Indeed, a small proportion
of islet autoantibody-positive children in the TEDDY
study first developed evidence of islet autoimmunity at
the age of 3 months [34]. IAA appearing early in life tend
to be high affinity of the IgG1 subclass. Rapid spreading
of the immune response to other islet autoantigens occurs
in early onset cases while those who progress to clinical
symptoms later in life more frequently have low-affinity
autoantibodies and atypical epitope reactivities [35]. A
study of progression in the US-based DAISY cohort
showed that age at onset of diabetes is closely correlated
with the age of appearance of the first islet autoantibodies
and the level of antibodies to insulin, but not glutamic
acid decarboxylase (GAD) or islet antigen 2 (IA-2) [36].
A follow-up study of the 118 multiple islet autoantibody-
positive individuals in DAISY showed that islet autoanti-
bodies appear later and at lower levels in the 27 slow
progressors compared with those who progressed [37].
In the Belgian Diabetes Registry, the 20-year progression
rate of multiple islet autoantibody-positive siblings and
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Fig. 1 Timeline towards focused study of type 1 diabetes in childhood
populations. In the 1970s, data from pancreatic histology, the description
of islet antibodies and genetic association with HLA confirmed the
autoimmune basis of the condition. The observation of increased HLA
mediated susceptibility in those developing the condition young, and the
need for defined phenotypes for successful GWAS has resulted in
excellent characterisation of early-onset diabetes but relative lack of
understanding of the pathogenesis of adult onset type 1 diabetes
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offspring under 40 years of age was reported [38••]. Their
data mirrored the combined BABYDIAB, DAISY and
DIPP birth cohort data [10] with the majority of multiple
islet autoantibody-positive individuals developing diabe-
tes within 20 years. Risk was not assessed in parents, and
this may contribute to the difference in number of slow
progressors observed as SNAIL includes parents as well
as siblings and offspring of individuals with diabetes. The
ethnic composition of most studies is predominantly
Caucasian apart from DAISY which includes four
Hispanic slow progressors. In the TEDDY study, where
8503 children were followed to age 6 (and more recently
8 years), an early peak of IAA only in 43% of children
who seroconverted within the first year of life declined
over the following 5 years and 38% had GADA only,
which increased until the second year of life and remained
relatively constant over the follow-up period [39, 40].
This suggests heterogeneity in early islet autoimmunity,
but ultimately, there is epitope spreading in most child-
hood cases before diagnosis.
Could There also Be Heterogeneity in Adult
Onset T1D? What Are the Islet Autoantibody
Patterns in Slow Progressors?
All SNAIL participants had, by definition, multiple islet auto-
antibodies [13••], but the autoantibody patterns varied be-
tween cohorts. The first antibodies detected in about two
thirds of children in BABYDIAB were IAA. Loss of IAA
has been associated with delayed progression [41••]. Further
development of the algorithm used in this study to analyse
longitudinal data from the TEDDY cohort identified clusters
with stratified risk profiles varying from 6 to 84% risk of
progression within 5 years [42••]. In the SNAIL cohorts,
IAA were more common in the first mAab positive samples
from BABYDIAB and ABIS children. Unexpectedly despite
most being tested first as adults, half of BOX and Pittsburgh
family study participants were also IAA positive in their first
sample. GADA are the first islet autoantibodies detected in
about a third of children who develop diabetes, but are also
prevalent in adult onset disease. GADAwere common in all
SNAIL cohorts, but overall were more frequent in older indi-
viduals. Antibodies that recognise IA-2 and ZnT8 are consid-
ered to develop later in the pathogenesis of T1D and are as-
sociated with progression. It is counterintuitive therefore that
ZnT8A were the second most frequent antibody in slow
progressors with no differences observed between autoanti-
bodies to the ZnT8 R325W variants. In contrast, IA-2Awere
less common, and BABYDIAB participants had a particularly
low prevalence of IA-2A (14%) in their first mAab sample.
Indepth analysis of autoantibody epitopes and IgG subclasses
in slow vs. rapid progressors is ongoing. During follow-up,
however, 18 of 22 (82%) BABYDIAB SNAIL participants
seroconverted to IA-2A positivity indicating that antigen
spreading continued in these individuals despite slower
progression.
Latent Autoimmune Diabetes in Adults
The most common screening tool for LADA are GADA.
An assay targeting terminally truncated (aa96-585) GAD
[43] improved the clinical phenotyping of LADA and
identified those with an increased need for insulin therapy
[44]. What would a screen of the general adult population
for IAA/truncated GADA/IA2-A and ZnT8A show? This
will be an important focus for studies of adult onset T1D
moving forward.
Immune Cell Subsets
Upregulation of MHC class I on beta cells and insulitis
dominated by CD8+ T cells are recognised as major de-
terminants of beta cell destruction, and this process is
variable both between and within pancreas samples
[45–47]. Mechanistically, beta cell destruction can involve
the release of cytolytic granules containing perforin and
granzyme by CD8+ T cells or be mediated through Fas
and Fas ligand-dependent interactions, while CD4+ T
cells provide help. Measures of CD8+ T and CD4+ T
function in at-risk individuals may therefore provide in-
sights into slow progression. In addition, advances in the
understanding of regulatory immune cell subsets have led
to studies indicating that although regulatory T cells ap-
pear to be normal in number, individuals with diabetes
have some functional defects in their regulatory T cells.
These include a reduced capacity to respond to IL2 [25].
In addition, effector T cells in those who develop diabetes
may be more resistant to regulation, as shown by a reduc-
tion in suppression of effector T cells by both naturally
occurring T regulatory cells and in vitro-generated adap-
tive T regulatory cells [48] and diminished IL2 respon-
siveness in antigen-experienced CD4+ T cells [49]. A
more recent report highlights the dynamic nature of im-
mune cell subsets with distinct immune pheontypes aris-
ing at various stages before diagnosis in “at risk” individ-
uals, and some of these are transient. For instance, chang-
es in IL2 responsiveness precede or coincide with tran-
siently altered B cell responses [50•]. This highlights the
need for longitudinal follow-up of immune cell subsets in
individuals with multiple islet autoantibodies, investiga-
tions which are currently ongoing in SNAIL.
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Conclusions
Apart from TrialNet and the Belgian Diabetes Registry,
most longitudinal research studies in T1D have focused
upon enrolling high-risk children at birth identified
through family history of disease or genetic risk. This has
led to limits in understanding the development of the dis-
ease in adults and the general population. Cross-sectional
studies in adults have suggested that GADA are the most
common islet autoantibody, but interpretation is limited by
the different definitions of diabetes and durations of dis-
ease at sampling. In the UK, adult diabetes care is conduct-
ed by primary care physicians, and therefore, it is challeng-
ing to collect routine data from adults. Furthermore, the
outdated islet cell autoantibody (ICA) assay is still often
used routinely rather than antigen-specific assays for
immunophenotyping/characterising individuals and this
can make comparisons difficult. The Islet Autoantibody
Standardization Programme (IASP) has identified high-
quality assays including ELISAS, radioimmunoassays
(RIA), luciferase immunoprecipitation system (LIPS) as-
says and agglutination PCR which are easier to perform
than ICA assays and will provide improved characterisa-
tion of islet autoantibodies at diagnosis of T1D.
In addition, we have limited understanding of the factors
that contribute to differences in incidence between countries
and this may be exacerbated by the recruitment of individuals
with similar high genetic risk for studies of diabetes. Cross-
sectional screens of the general population in countries with
differing incidence (Finland vs Russian Karelia [48] and the
UK vs Lithuania [49]) suggested some geographical differ-
ences in islet autoantibody profiles in childhood. Follow-up
of autoantibody-positive individuals in the general population
from birth as well as extended follow-up of existing cohorts is
warranted to establish answers to the questions set out in this
review.
One unexpected outcome of our studies of slow progres-
sion to T1D is that it has highlighted the knowledge gaps in
understanding the pathogenesis of the disease adult onset
cases.
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